The Medicines Company, a pharmaceutical company, specializes in acute care hospital products. It engages in the acquisition, development, and commercialization of late-stage development drugs. The company offers Angiomax, a direct thrombin inhibitor for use as an anticoagulant in patients with unstable angina undergoing percutaneous coronary interventions or coronary angioplasty. It also develops clevidipine, an intravenous drug intended for the short-term control of blood pressure in intensive care patients; and cangrelor, an antiplatelet agent that prevents platelet activation and aggregation for the treatment of vascular disease. The company’s customers include hospital...